logo
Plus   Neg
Share
Email

Alnylam Reports Promising Interim Results From Phase 1 Study On Hypertension Treatment

Alnylam Pharmaceuticals Inc. (ALNY) said that an interim Phase 1 study results of ALN-AGT suggesting a dose-dependent and sustained reduction in blood pressure persisting up to 3 months after a single subcutaneous dose are promising and may offer a novel path to securing better treatment adherence and improved blood pressure control. Further study to establish the safety and clinical efficacy of the approach seems warranted.

ALN-AGT is a subcutaneous investigational RNAi therapeutic targeting liver-expressed angiotensinogen (AGT) for the treatment of hypertension.

ALN-AGT was shown to be generally well tolerated, with no treatment-related serious adverse events or study discontinuations.

Compared to placebo, patients treated with ALN-AGT experienced dose-dependent reductions in serum AGT — the sole precursor of all angiotensin peptides, including the potent vasoconstrictor angiotensin (Ang) II.

In the 200 mg dose cohort, the mean reduction of AGT at 8 weeks was 94.9 +/- 1.6 percent.

Reductions of more than 90 percent persisting through 12 weeks after single doses of 100 or 200 mg were observed, with up to 97.6 percent AGT knockdown at 200 mg. The durability of AGT knockdown supports the potential for once quarterly dosing and possibly even less frequent dosing.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Kimberly-Clark Corp. (KMB) on Monday reported a profit for the fourth quarter that edged down from last year, hurt by higher expenses, despite 6 percent sales growth. Both adjusted earnings per share and net sales topped analysts' expectations. The company also initiated adjusted earnings and net sales growth guidance for the full-year 2021. Shares of Philips Electronics NV were gaining around 3 percent in Amsterdam trading after the Dutch consumer electronics giant reported Monday higher results in its fourth quarter. The company also proposed dividend, and said it sees growth in fiscal 2021 comparable sales and adjusted margin. Luxury chocolatier Godiva announced its plans to close or sell all of its stores in the United States due to weak in-store visits amid the ongoing coronavirus pandemic. However, the company will continue to sell its products online, at grocery and other stores. All its stores across Europe, Middle East and Greater China will continue its operations.
Follow RTT